SAREPTA THERAPEUTICS INC (SRPT)
US8036071004 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to SRPT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 169.21. This target is 32.82% above the current price.
SRPT was analyzed by 30 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about SRPT.
In the previous month the buy percentage consensus was at a similar level.
SRPT was analyzed by 30 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-01 | UBS | Maintains | Buy -> Buy |
| 2024-02-29 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2024-02-29 | Needham | Maintains | Buy -> Buy |
| 2024-02-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-29 | Citigroup | Maintains | Buy -> Buy |
| 2024-02-20 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-02-20 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-02-16 | Needham | Maintains | Buy -> Buy |
| 2024-02-15 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2024-02-14 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2024-02-14 | Mizuho | Maintains | Buy -> Buy |
| 2024-01-31 | BMO Capital | Initiate | Outperform |
| 2024-01-30 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-01-29 | Needham | Reiterate | Buy -> Buy |
| 2024-01-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-01-10 | Needham | Maintains | Buy -> Buy |
| 2024-01-09 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-12-13 | Citigroup | Initiate | Buy |
| 2023-12-12 | Deutsche Bank | Initiate | Buy |
| 2023-11-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-11-21 | Wedbush | Initiate | Outperform |
| 2023-11-02 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2023-11-02 | Needham | Maintains | Buy -> Buy |
| 2023-11-02 | Barclays | Maintains | Overweight -> Overweight |
| 2023-10-31 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-10-31 | Needham | Maintains | Buy -> Buy |
| 2023-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-10-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-10-31 | Morgan Stanley | Maintains | Overweight -> Overweight |